首页> 外文期刊>BMC Infectious Diseases >Rapid and accurate detection of RMP- and INH- resistant Mycobacterium tuberculosis in spinal tuberculosis specimens by CapitalBio? DNA microarray: A prospective validation study
【24h】

Rapid and accurate detection of RMP- and INH- resistant Mycobacterium tuberculosis in spinal tuberculosis specimens by CapitalBio? DNA microarray: A prospective validation study

机译:通过CapitalBio?快速准确地检测出脊柱结核标本中耐RMP和INH的结核分枝杆菌。 DNA微阵列:前瞻性验证研究

获取原文
           

摘要

Background DNA microarrays can detect tuberculosis and its multi-drug resistant form in M. tuberculosis isolates and sputum specimens with high sensitivity and specificity. However, no performance data currently exists for its use in spinal tuberculosis specimens. This study was aimed to assess the performance of the CapitalBio? DNA microarray in the detection of isoniazid (INH) and rifampicin (RMP) resistance in spinal tuberculosis compared with the BACT/MGIT 960 system. Methods From March 2009 to December 2011, 153 consecutive patients from Southwest Hospital, Chongqing with clinically and pathologically diagnosed spinal tuberculosis were enrolled into this study. Specimens collected during surgery from the tuberculosis patients were subjected to M. tuberculosis species identification and drug-resistance detection by the CapitalBio? DNA microarray, and results were compared with those obtained from the absolute concentration drug susceptibility testing. Results The CapitalBio? DNA microarray achieved 93.55% sensitivity for the correct M. tuberculosis species identification of the 93 specimens that tested positive for spinal tuberculosis through culture. In addition, twenty-seven additional patients (45.0%) were detected by the DNA microarray to be positive for M. tuberculosis among sixty spinal tuberculosis patients who were culture negative. Moreover, the DNA microarray had a sensitivity of 88.9% and a specificity of 90.7% for RMP resistance, and the microarray had a sensitivity of 80.0% and a specificity of 91.0% for INH resistance. The mean turn-around time of M. tuberculosis species identification and drug resistance detection using the DNA microarray was 5.8 (range, 4–9) hours. Conclusions The CapitalBio? DNA microarray is a feasible and accurate tool for the species identification of M. tuberculosis and for directly detecting RMP and INH resistance from spinal tuberculosis specimens in fewer than 9 hours.
机译:背景DNA微阵列可以高灵敏度和特异性检测结核分枝杆菌分离株和痰标本中的结核及其多药耐药形式。但是,目前尚无用于脊椎结核标本的性能数据。这项研究旨在评估CapitalBio?的性能。与BACT / MGIT 960系统相比,DNA芯片可检测脊柱结核中的异烟肼(INH)和利福平(RMP)耐药性。方法2009年3月至2011年12月,重庆市西南医院连续153例经临床和病理学诊断为脊柱结核的患者入选本研究。在手术期间从结核病患者中收集的标本经过CapitalBio?进行结核分枝杆菌物种鉴定和耐药性检测。 DNA微阵列,并将结果与​​从绝对浓度药物敏感性测试获得的结果进行比较。结果CapitalBio?通过对93份经培养呈阳性的结核病标本进行鉴定,DNA芯片对正确鉴定结核分枝杆菌种的灵敏度达到93.55%。此外,在60例培养阴性的脊椎结核患者中,DNA微阵列检测到另外2​​7例患者(45.0%)结核分枝杆菌阳性。此外,DNA微阵列对RMP抗性的敏感性为88.9%,特异性为90.7%,而微阵列对INH抗性的敏感性为80.0%,特异性为91.0%。使用DNA微阵列进行结核分枝杆菌物种鉴定和耐药性检测的平均周转时间为5.8(范围为4–9)小时。结论CapitalBio? DNA微阵列是一种可行,准确的工具,可用于在不到9小时的时间内鉴定结核分枝杆菌的种类以及直接检测脊柱结核标本对RMP和INH的抵抗力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号